Although access to novel technologies has increased and insights in biology and underlying disease mechanisms have improved immensely over the last decades, less innovative molecules are currently being approved and successfully launched by pharmaceutical industry. Some of the reasons are that development costs increased dramatically over the last two decades while productivity stagnated or declined, competition for in-licensing increased and marketing costs rose significantly, and regulatory scrutiny has mounted. As a result of these challenges growth and profitability of pharmaceutical industry declines. Therefore, new business models for the industry are required in order to respond to challenges imposed by economical conditions and by increased pressure of aging global population, eager to secure and to finance the new era of medicine leading to additional prolongation of life expectancy and improvement of quality of life at advanced age. The response to this new realm is the focus to therapeutic areas of strength and migration towards life-saving medicines. Therefore, continuation of prosperity of pharmaceutical industry requires profound changes in the research and development and sales organizations; the old paradigm of decision-making and existing power structures dictate if and how breakthrough scientific innovation, new technologies and insights are applied. Instead, the next pharmaceutical industry needs to radically reshape its business model to enable sustained growth and high profitability coupled with leadership in medical progress and innovation.